Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Mirum Pharmaceuticals (MIRM)

Mirum Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MIRM
DateTimeSourceHeadlineSymbolCompany
10/12/202423:00Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
15/11/202422:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRMMirum Pharmaceuticals Inc
14/11/202413:00Business WireMirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202416:44Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202413:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRMMirum Pharmaceuticals Inc
12/11/202413:00Business WireMirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
08/11/202423:30Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
07/11/202421:30Business WireMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:MIRMMirum Pharmaceuticals Inc
04/11/202421:30Business WireMirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
31/10/202412:30Business WireMirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingNASDAQ:MIRMMirum Pharmaceuticals Inc
22/10/202422:06Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MIRMMirum Pharmaceuticals Inc
10/10/202423:30Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
10/10/202412:30Business WireVolixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary CholangitisNASDAQ:MIRMMirum Pharmaceuticals Inc
11/09/202400:45Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
28/08/202420:01Business WireMirum Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:MIRMMirum Pharmaceuticals Inc
09/08/202423:00Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202420:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202420:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRMMirum Pharmaceuticals Inc
07/08/202420:01Business WireMirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:MIRMMirum Pharmaceuticals Inc
31/07/202420:30Business WireMirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
25/07/202412:30Business WireMirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and OlderNASDAQ:MIRMMirum Pharmaceuticals Inc
10/07/202423:00Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202420:46Business WireApprobation du LIVMARLI de Mirum Pharmaceuticals dans l'Union européenne pour les patients atteints de PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202420:20Business WireLIVMARLI von Mirum Pharmaceuticals wird in der Europäischen Union für Patienten mit PFIC zugelassenNASDAQ:MIRMMirum Pharmaceuticals Inc
08/07/202412:30Business WireMirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFICNASDAQ:MIRMMirum Pharmaceuticals Inc
28/06/202412:30Business WireMirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTXNASDAQ:MIRMMirum Pharmaceuticals Inc
17/06/202412:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRMMirum Pharmaceuticals Inc
17/06/202412:00Business WireMirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC StudiesNASDAQ:MIRMMirum Pharmaceuticals Inc
16/06/202421:00Business WireMirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024NASDAQ:MIRMMirum Pharmaceuticals Inc
11/06/202402:00Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MIRMMirum Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIRM